LORIA, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.837
AS - Asia 11.074
EU - Europa 9.407
SA - Sud America 1.356
AF - Africa 207
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 11
Totale 45.918
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.601
SG - Singapore 3.509
CN - Cina 3.287
GB - Regno Unito 3.140
HK - Hong Kong 1.469
IT - Italia 1.254
BR - Brasile 1.017
DE - Germania 989
VN - Vietnam 976
SE - Svezia 964
FI - Finlandia 746
UA - Ucraina 568
TR - Turchia 531
FR - Francia 400
RU - Federazione Russa 391
PL - Polonia 370
KR - Corea 304
BG - Bulgaria 213
IN - India 205
BD - Bangladesh 138
AR - Argentina 122
MX - Messico 89
CA - Canada 87
IQ - Iraq 87
ID - Indonesia 77
NL - Olanda 77
JP - Giappone 74
ZA - Sudafrica 52
PK - Pakistan 50
ES - Italia 46
VE - Venezuela 46
AE - Emirati Arabi Uniti 45
EC - Ecuador 42
MY - Malesia 35
BE - Belgio 34
CO - Colombia 33
PH - Filippine 33
MA - Marocco 32
UZ - Uzbekistan 32
AT - Austria 30
CL - Cile 29
TW - Taiwan 29
LT - Lituania 25
SA - Arabia Saudita 25
EG - Egitto 24
IE - Irlanda 24
JO - Giordania 23
PY - Paraguay 23
CZ - Repubblica Ceca 21
GR - Grecia 20
RO - Romania 18
AU - Australia 16
BO - Bolivia 16
NP - Nepal 16
PE - Perù 16
DZ - Algeria 15
IR - Iran 15
AZ - Azerbaigian 14
CR - Costa Rica 14
KE - Kenya 14
TH - Thailandia 14
ET - Etiopia 13
OM - Oman 13
TN - Tunisia 12
CH - Svizzera 11
IL - Israele 11
NG - Nigeria 10
UY - Uruguay 10
BY - Bielorussia 9
DO - Repubblica Dominicana 9
JM - Giamaica 9
KZ - Kazakistan 9
AL - Albania 8
RS - Serbia 8
SI - Slovenia 8
EU - Europa 7
NI - Nicaragua 7
NZ - Nuova Zelanda 7
GE - Georgia 6
LB - Libano 6
SC - Seychelles 6
SN - Senegal 6
BA - Bosnia-Erzegovina 5
HN - Honduras 5
HU - Ungheria 5
PA - Panama 5
QA - Qatar 5
UG - Uganda 5
AM - Armenia 4
AO - Angola 4
BH - Bahrain 4
CY - Cipro 4
KG - Kirghizistan 4
NO - Norvegia 4
HR - Croazia 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MD - Moldavia 3
MM - Myanmar 3
Totale 45.863
Salva come PNG Salva come JPEG
Città #
Singapore 2.406
Fairfield 2.192
Southend 2.017
Santa Clara 1.990
Ashburn 1.902
Woodbridge 1.601
Hong Kong 1.455
Houston 1.294
Jacksonville 1.230
Chandler 1.197
Hefei 1.151
San Jose 852
Seattle 840
Wilmington 801
Dearborn 796
Ann Arbor 776
Cambridge 720
Beijing 592
Chicago 573
Nyköping 546
London 521
Helsinki 508
Los Angeles 439
Warsaw 358
Ho Chi Minh City 309
The Dalles 307
Modena 306
Seoul 287
Izmir 285
New York 244
San Diego 235
Hanoi 234
Princeton 220
Sofia 207
Salt Lake City 206
Eugene 201
Des Moines 169
Council Bluffs 168
Lauterbourg 167
Munich 139
Tampa 130
Shanghai 129
Moscow 124
Buffalo 115
Dallas 102
Grafing 101
São Paulo 97
Elk Grove Village 95
Columbus 86
Falls Church 86
Milan 75
Orem 74
Rome 72
Bremen 58
Sterling 57
Guangzhou 53
Tokyo 51
Kunming 48
Da Nang 47
Boardman 46
Frankfurt am Main 45
Istanbul 44
Phoenix 44
Jakarta 43
Baghdad 41
Redwood City 39
Lancaster 38
Rio de Janeiro 38
Turku 38
Haiphong 37
Miami 35
Norwalk 35
San Mateo 34
Fremont 32
Bologna 31
Brooklyn 31
Detroit 31
Kent 31
Amsterdam 30
Chennai 29
Manchester 29
Mexico City 29
Atlanta 28
Brussels 28
San Francisco 28
Dulles 26
Falkenstein 25
Montreal 25
Tashkent 25
Johannesburg 24
Bari 23
Biên Hòa 23
Kilburn 23
Denver 22
Poplar 22
Dhaka 21
Dublin 21
Stockholm 21
Toronto 21
Verona 21
Totale 33.298
Salva come PNG Salva come JPEG
Nome #
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population 696
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: A possible compensatory mechanism. 445
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study 428
Gender, fatty liver and GGT 414
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes 408
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors 406
Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. 403
Effect of liver cirrhosis on the systemic availability of naltrexone in humans 393
Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. 390
Review article: the metabolic syndrome and non-alcoholic fatty liver disease 375
Review article: diabetes, genetics and ethnicity 366
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. 354
Suppression of bile acid synthesis, but not of hepatic cholesterol 7alpha-hydroxylase expression, by obstructive cholestasis in humans 351
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 351
Herpesvirus DNA is frequently detected in liver tissue from hepatitis C patients 345
Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. 341
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? 341
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity 340
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: Prevalence and correlates 335
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients 333
Endocrine and liver interaction: the role of endocrine pathways in NASH 331
Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease 327
Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis 319
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis 314
Nonalcoholic fatty liver disease and aging: epidemiology to management 311
Statins in liver disease: a molehill, an iceberg, or neither? 309
Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: Insights from evidence on hepatic cholesterol degradation and gallstone disease in humans 308
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD 303
Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. 303
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 299
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. 299
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 299
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? 297
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? 297
In Vivo Degradation of Cholesterol to Bile Acids Is Reduced in Patients Receiving Parenteral Nutrition. 293
Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. 289
Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation. 285
Liver and kidney foreign bodies granulomatosis in a patient with malocclusion, bruxism, and worn dental prostheses 285
Advances in the comprehension of the pathophysiology of bile secretion 284
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis 283
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD) 281
'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis 279
Chicken or egg turned into head or belly 277
Il pool degli acidi biliari quale regolatore del metabolismo epatico del colesterolo: sintesi degli acidi biliari. 277
Risk for cardiovascular events in an Italian population of patients with type 2 diabetes 276
From NAFLD in clinical practice to answers from guidelines. 275
Hepatic nuclear receptors in human cholelithiasis: A link with insulin resistance? 272
MR techniques in the qualitative analysis of liver steatosis: the potential in the differentiation between steatohepatatis and steatosis 271
Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. 271
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic Fatty liver disease: a novel approach to reduce cardiovascular risk? 270
Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. 270
Is cholangiocarcinoma another complication of insulin resistance: A report of three cases 269
Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus - A prospective, double-blind, randomized study 268
Relationship of serum fetuin-a levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. 267
Apolipoprotein synthesis in nonalcoholic steatohepatitis 266
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question 266
Anatomia e fisiologia delle vie biliari 266
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 265
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 264
Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study 262
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. 260
Effects of acute changes of bile acid pool composition on biliary lipid secretion 258
Review article: hepatic steatosis and insulin resistance 256
Determinants of bile secretion: effect of bile salt structure on bile flow and biliary cation secretion 256
Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans 250
Cardiovascular and systemic risk in nonalcoholic fatty liver disease -Atherosclerosis as a major player in the natural course of NAFLD 250
Bile acid structure and regulation of biliary protein secretion and composition in man 249
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. 248
MOLECULAR REGULATION OF STEROL METABOLISM BY BILE ACIDS IN CULTURED HUMAN HEPATOCYTES 248
Effect of ursocholic acid on bile lipid secretion and composition 247
Hepatitis C and diabetes: the inevitable coincidence? 247
Growth hormone plasma levels in nonalcoholic fatty liver disease 246
Diet and gallstones in Italy: the cross-sectional MICOL results. 245
The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption. 244
Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid. 244
NAFLD AND TYPE 2 DIABETES: A GENETIC OR METABOLIC ISSUE? 243
Risk factors for hospital readmission of elderly patients 242
Influence of age and sex on serum concentrations of total dimeric activin A 241
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia? 240
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project) 240
Clinical physiology of NAFLD: A critical overview of pathogenesis and treatment 238
Multiecho MR sequences and high-resolution magic angle spinning (HRMAS)ex-vivo spectroscopy in the qualitative analysis and differentiationbetween steatohepatitis and steatosis 237
Cholesterol absorption in cirrhosis: the role of total and individual bile acid pool size 236
Effect of diabetic autonomic neuropathy on gallbladder kinetics in insulin dependent diabetic patients 233
ESTIMATION OF CARDIOVASCULAR RISK IN TYPE 2 DIABETES 233
Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. 233
Patogenesi della colelitiasi. I. Colelitiasi colesterinica. 231
Nonalcoholic fatty liver disease induced by leuprorelin acetate 231
The prediction of coronary heart disease mortality as a function of major risk factors in over 30.000 men in the italian RIFLE Pooling Project. A comparison with the MRFIT primary screenees 230
Bile acid composition and hepatic sterol metabolism in man. The effect of deoxycholic acid administration. 230
Cholesterol metabolism in gallstone disease .Preliminary evidence from the analysis of circulating markers of sterol homeostasis 230
Short-term effects of simvastatin on bile acid synthesis and biliary lipid secretion in human subjects. 228
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. 228
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease 227
Non-alcoholic Fatty Liver Disease: a HR-MAS analysis 226
Heart failure and chronic kidney disease in a registry of internal medicine wards 225
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid 224
NAFLD and cardiovascular risk: direct evidence for the tale of two ages. 222
Bile acid and hepatocyte death 222
HEPATIC NUCLEAR RECEPTOR EXPRESSION AND REGULATION OF BILE ACID SYNTHESIS IN HUMANS 222
Totale 28.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 172.985
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 172.985
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021855 0 0 0 0 0 0 0 0 0 452 257 146
2021/20223.583 51 502 394 313 87 156 261 204 392 213 607 403
2022/20233.279 363 354 205 326 401 583 72 310 385 29 142 109
2023/20242.003 84 119 114 136 457 221 216 286 56 42 75 197
2024/20257.463 263 87 129 495 1.607 971 588 413 707 257 838 1.108
2025/202614.190 897 613 1.224 1.896 2.968 1.580 1.933 628 1.369 1.082 0 0
Totale 46.070